The First Cancer Immunotherapy ETF (CNCR) ETF

Expense Ratio: 0.79% | AUM: 28.98M | Issuer: Loncar Cancer Immunotheraphy

CNCR Daily Price Range
CNCR 52-Week Price Range

CNCR - Real-Time SMART Grade™

B
Buy

Overall SMART Grade

CNCR has a real-time SMART Grade of B (Buy).

Learn More About SMART Grades™

CNCR - Profile & Info


The investment objective of the Loncar Cancer Immunotherapy ETF seeks to replicate the Loncar Cancer Immunotherapy Index. The index was developed by a top biologist and includes large pharmaceutical and growth-oriented biotechnology firms that are focused on improving cancer treatments.

Issuer Loncar Cancer Immunotheraphy
Expense Ratio 0.79%
Assets Under Management (AUM) 28.98M
Underlying Index Loncar Cancer Immunotherapy Index
Asset Class Equity
ETF Category Health & Biotech ETFs
Options? No
Total Holdings N/A

CNCR - News


View All CNCR News

CNCR - Price/Volume Stats

Current price $24.17
Prev. close $24.15
Day low $23.94
Day high $24.29
52-week high $26.47
52-week low $19.82
Day Volume 18,962
Avg. volume 16,611
Dividend yield 0.47%

CNCR - Recent Returns

1-mo 2.55%
3-mo 13.79%
6-mo -6.35%
1-year 13.90%
3-year N/A
5-year N/A
YTD 13.79%
2016 -25.63%
2015 N/A
2014 N/A
2013 N/A
2012 N/A

CNCR - Stock Chart


CNCR - Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
Page generated in 2.1503 seconds.